+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Neuromodulation Market - Global Forecast 2026-2032- Product Image
Neuromodulation Market - Global Forecast 2026-2032- Product Image
Sale

Neuromodulation Market - Global Forecast 2026-2032

  • Report

  • 185 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4968620
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Neuromodulation Market is projected to reach USD 7.06 Billion in 2026. It is expected to continue growing at a CAGR of 7.04%, reaching USD 10.65 Billion by 2032.

Neuromodulation is moving from a niche implantable-device category to a core pillar of precision neuroscience, chronic pain care, movement disorder management, epilepsy treatment, psychiatric care, and pelvic health. The field is anchored by clinically established modalities such as spinal cord stimulation, deep brain stimulation, vagus nerve stimulation, sacral nerve stimulation, transcranial magnetic stimulation, and emerging peripheral nerve stimulation platforms.

Demand is supported by measurable disease burden: the WHO identifies neurological conditions as a leading global cause of illness and disability, Parkinson’s disease affected more than 8.5 million people in 2019, epilepsy affects about 50 million people worldwide, and the CDC reported chronic pain in roughly one in five U.S. adults. These realities make neuromodulation a strategically important field for payers, hospitals, device manufacturers, clinicians, and digital health innovators seeking durable, patient-specific alternatives to medication-only care.

Transformative Shifts in the Neuromodulation Landscape

The neuromodulation landscape is being reshaped by miniaturized implants, rechargeable and recharge-free power systems, MRI-conditional devices, directional leads, remote programming, and less invasive delivery approaches. These advances are improving patient selection, therapy durability, stimulation precision, and post-implant management while reducing friction for clinicians and care teams.

At the same time, value-based healthcare is changing purchasing behavior. Hospitals and payers increasingly expect real-world evidence, patient-reported outcomes, fewer revision procedures, and clear cost offsets from reduced medication dependence, fewer hospital visits, and improved functional status. Regulatory scrutiny is also raising the importance of post-market surveillance, cybersecurity, usability, and long-term device reliability across implantable and noninvasive neuromodulation systems.

Cumulative Impact of Artificial Intelligence in Neuromodulation

Artificial intelligence is creating cumulative impact across the neuromodulation pathway, from patient identification and imaging analytics to signal interpretation, therapy optimization, and remote follow-up. AI-enabled analytics can help clinicians detect response patterns in electrophysiology, wearable data, imaging, and patient-reported outcomes, supporting more personalized stimulation parameters and earlier intervention when therapy response changes.

The most important long-term opportunity is closed-loop neuromodulation, where devices sense neural or physiologic signals and adjust stimulation in response. FDA-authorized sensing-capable deep brain stimulation systems and remote monitoring tools demonstrate the direction of travel, although algorithm validation, cybersecurity, data governance, bias mitigation, interoperability, and clinical accountability remain essential adoption requirements.

Key Regional Insights: Asia-Pacific, North America, Latin America, Europe, Middle East, and Africa

North America remains the most mature neuromodulation region due to high specialist density, FDA-cleared device availability, established reimbursement pathways, NIH-supported neuroscience research, and large chronic pain, epilepsy, and movement disorder populations. Europe continues to be a major clinical and regulatory hub, with Germany, France, Italy, Spain, and the United Kingdom contributing strong neurology, neurosurgery, rehabilitation, and pain-management infrastructure while adapting to stricter EU Medical Device Regulation requirements and health technology assessment expectations.

Asia-Pacific is the fastest-evolving opportunity as Japan, China, South Korea, Australia, and India expand access to advanced neurological care, imaging capacity, and hospital-based device programs. Latin America is led by Brazil and Mexico, where private healthcare expansion and specialist centers support adoption, although reimbursement and affordability constraints remain material barriers. The Middle East, especially GCC health systems, is investing in specialty hospitals, advanced procedures, and medical technology infrastructure, while Africa’s adoption is concentrated in select urban centers where neurosurgical capacity, referral networks, and private-sector access are available.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN markets are gaining relevance through medical tourism, private hospital networks, and specialist centers in Singapore, Thailand, and Malaysia, while broader access remains uneven across lower-income member states due to reimbursement gaps and workforce limitations. The GCC is advancing neuromodulation adoption through government-backed healthcare modernization, premium hospital procurement, and rising demand for pain, movement disorder, epilepsy, and rehabilitation services.

The European Union is influential because MDR compliance, health technology assessment processes, and cross-border clinical evidence shape global commercialization standards. BRICS economies offer scale through China, India, Brazil, Russia, and South Africa, but pricing, reimbursement, public procurement, and local manufacturing expectations vary significantly. G7 markets remain the benchmark for clinical evidence, specialist adoption, regulatory discipline, and reimbursement scrutiny, while NATO countries overlap with advanced defense-health priorities involving traumatic injury, chronic pain, rehabilitation, mental health, and neurotechnology research.

Key Country Insights Across Major Neuromodulation Markets

The United States is the global commercial anchor for neuromodulation, supported by FDA pathways, large hospital systems, Medicare coverage dynamics, clinical trial activity, and high chronic pain prevalence. Canada follows a more centralized access model shaped by provincial reimbursement, health technology assessment, and specialist referral pathways. Mexico and Brazil represent the strongest Latin American opportunities due to large patient pools, expanding private healthcare access, and growing neurology and pain-management capacity.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine specialist expertise with reimbursement scrutiny, structured clinical evaluation, and increasing demand from aging populations, while Russia’s market is shaped by public procurement and localized access. China is scaling rapidly through hospital investment, domestic medtech capabilities, and neurological care expansion; India combines high unmet need with price sensitivity and uneven specialist access; Japan has deep aging-related demand and advanced clinical infrastructure; South Korea is technology-forward with strong digital health readiness; and Australia benefits from advanced clinical practice, specialist centers, and structured reimbursement pathways.

Actionable Recommendations for Neuromodulation Industry Leaders

Industry leaders should prioritize evidence generation that links neuromodulation to functional improvement, medication reduction, quality-of-life gains, durable symptom control, and lower total cost of care. Market access teams should build payer-ready dossiers using randomized evidence, registries, real-world outcomes, patient-reported measures, and subgroup analyses for chronic pain, Parkinson’s disease, epilepsy, depression, overactive bladder, and pelvic health.

Organizations should also invest in AI-enabled programming, cybersecurity-by-design, clinician training, patient education, remote follow-up, and post-market surveillance. Strategic partnerships with hospitals, academic centers, digital health developers, and local distributors will be critical for scaling access in Asia-Pacific, Latin America, the Middle East, and other underpenetrated regions. Leaders should align product design with MRI compatibility, battery longevity, workflow efficiency, and transparent data governance to support adoption by clinicians, payers, and regulators.

Research Methodology

This executive summary is built from a structured secondary-research methodology using publicly available and verifiable sources, including regulatory databases, clinical guidelines, peer-reviewed literature, government health statistics, hospital procurement signals, reimbursement frameworks, and recognized public health organizations such as the WHO, CDC, FDA, NIH, and European regulatory authorities.

Insights were synthesized across disease burden, device innovation, clinical evidence, regulatory pathways, reimbursement maturity, regional healthcare infrastructure, workforce capacity, and adoption indicators. The approach emphasizes data-backed interpretation rather than speculative forecasting, ensuring that strategic conclusions remain credible for executives, investors, manufacturers, healthcare providers, and policy decision-makers.

Conclusion

Neuromodulation is entering a new growth phase defined by precision stimulation, AI-supported personalization, remote care, and stronger outcome accountability. The category is supported by durable clinical need across chronic pain, movement disorders, epilepsy, psychiatric disorders, pelvic health, and autonomic conditions, making it one of the most strategically important segments in neurotechnology.

Future leadership will depend on clinical evidence, reimbursement alignment, responsible AI, device reliability, patient access, and regional execution. Organizations that combine innovation with measurable patient outcomes, secure digital infrastructure, and disciplined market access strategies will be best positioned as neuromodulation becomes more integrated into mainstream neurological, psychiatric, rehabilitation, and pain-management care.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Neuromodulation Market, by Product Type
7.1. Introduction
7.2. Deep Brain Stimulation
7.2.1. Directional
7.2.2. Ring
7.3. Sacral Nerve Stimulation
7.3.1. Nonrechargeable
7.3.2. Rechargeable
7.4. Spinal Cord Stimulation
7.4.1. Closed Loop
7.4.2. Open Loop
7.5. Transcutaneous Electrical Nerve Stimulation
7.5.1. Portable
7.5.2. Stationary
7.6. Vagus Nerve Stimulation
7.6.1. Implanted
7.6.2. Noninvasive
8. Neuromodulation Market, by Technology
8.1. Introduction
8.2. Invasive
8.3. Noninvasive
9. Neuromodulation Market, by Patient Age Group
9.1. Introduction
9.2. Pediatric
9.3. Adult
9.4. Geriatric
10. Neuromodulation Market, by Application
10.1. Introduction
10.2. Chronic Pain Management
10.3. Depression
10.4. Epilepsy
10.5. Movement Disorders
10.6. Urinary Incontinence
11. Neuromodulation Market, by End User
11.1. Introduction
11.2. Ambulatory Surgical Centers
11.3. Home Care
11.4. Hospitals
12. Neuromodulation Market, by Region
12.1. Asia-Pacific
12.2. North America
12.3. Latin America
12.4. Europe
12.5. Middle East
12.6. Africa
13. Neuromodulation Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Neuromodulation Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Abbott Laboratories
16.2. BioControl by Merck
16.3. BioElectronics Corporation
16.4. Boston Scientific Corporation
16.5. EndoStim, Inc.
16.6. Impulse Dynamics
16.7. Livanova
16.8. Mainstay Medical
16.9. Medtronic PLC
16.10. MicroTransponde
16.11. NeuroMetrix
16.12. Neuronetics, Inc.
16.13. NeuroPace, Inc.
16.14. NeuroSigma, Inc.
16.15. Nevro Corp.
16.16. Saluda Medical
16.17. SceneRay Corporation, Limited
16.18. Soterix Medical
16.19. Synapse Biomedical
List of Figures
FIGURE 1. GLOBAL NEUROMODULATION MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL NEUROMODULATION MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL NEUROMODULATION MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL NEUROMODULATION MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL NEUROMODULATION MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
FIGURE 9. GLOBAL NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL NEUROMODULATION MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2032 (%)
FIGURE 11. GLOBAL NEUROMODULATION MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL NEUROMODULATION MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL NEUROMODULATION MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL NEUROMODULATION MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL NEUROMODULATION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL NEUROMODULATION MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL NEUROMODULATION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL NEUROMODULATION MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL NEUROMODULATION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL NEUROMODULATION MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL NEUROMODULATION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL NEUROMODULATION MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL NEUROMODULATION MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL NEUROMODULATION MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL NEUROMODULATION MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL DEEP BRAIN STIMULATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL DEEP BRAIN STIMULATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL DEEP BRAIN STIMULATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL DIRECTIONAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL DIRECTIONAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL DIRECTIONAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL RING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL RING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL RING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL SACRAL NERVE STIMULATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL SACRAL NERVE STIMULATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL SACRAL NERVE STIMULATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL NONRECHARGEABLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL NONRECHARGEABLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL NONRECHARGEABLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL RECHARGEABLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL RECHARGEABLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL RECHARGEABLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL SPINAL CORD STIMULATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL SPINAL CORD STIMULATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL SPINAL CORD STIMULATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL CLOSED LOOP MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL CLOSED LOOP MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL CLOSED LOOP MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL OPEN LOOP MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL OPEN LOOP MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL OPEN LOOP MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL PORTABLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL PORTABLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL PORTABLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL STATIONARY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL STATIONARY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL STATIONARY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL VAGUS NERVE STIMULATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL VAGUS NERVE STIMULATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL VAGUS NERVE STIMULATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL IMPLANTED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL IMPLANTED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL IMPLANTED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL NONINVASIVE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL NONINVASIVE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL NONINVASIVE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL INVASIVE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL INVASIVE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL INVASIVE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL NONINVASIVE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL NONINVASIVE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL NONINVASIVE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL NEUROMODULATION MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL ADULT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL ADULT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL NEUROMODULATION MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL CHRONIC PAIN MANAGEMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL CHRONIC PAIN MANAGEMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL CHRONIC PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL DEPRESSION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL DEPRESSION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL DEPRESSION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL EPILEPSY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL EPILEPSY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL EPILEPSY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL MOVEMENT DISORDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL MOVEMENT DISORDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL MOVEMENT DISORDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL URINARY INCONTINENCE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL URINARY INCONTINENCE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL URINARY INCONTINENCE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL NEUROMODULATION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL HOME CARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL HOME CARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL HOME CARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL NEUROMODULATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 93. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 94. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 95. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2017-2032 (USD MILLION)
TABLE 96. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 97. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2017-2032 (USD MILLION)
TABLE 98. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 99. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 100. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 101. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 102. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 103. ASIA-PACIFIC NEUROMODULATION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 104. NORTH AMERICA NEUROMODULATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 105. NORTH AMERICA NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 106. NORTH AMERICA NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2017-2032 (USD MILLION)
TABLE 107. NORTH AMERICA NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 108. NORTH AMERICA NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2017-2032 (USD MILLION)
TABLE 109. NORTH AMERICA NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 110. NORTH AMERICA NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 111. NORTH AMERICA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 112. NORTH AMERICA NEUROMODULATION MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 113. NORTH AMERICA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 114. NORTH AMERICA NEUROMODULATION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 115. LATIN AMERICA NEUROMODULATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 116. LATIN AMERICA NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 117. LATIN AMERICA NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2017-2032 (USD MILLION)
TABLE 118. LATIN AMERICA NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 119. LATIN AMERICA NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2017-2032 (USD MILLION)
TABLE 120. LATIN AMERICA NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 121. LATIN AMERICA NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 122. LATIN AMERICA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 123. LATIN AMERICA NEUROMODULATION MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 124. LATIN AMERICA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 125. LATIN AMERICA NEUROMODULATION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 126. EUROPE NEUROMODULATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 127. EUROPE NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 128. EUROPE NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2017-2032 (USD MILLION)
TABLE 129. EUROPE NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 130. EUROPE NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2017-2032 (USD MILLION)
TABLE 131. EUROPE NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 132. EUROPE NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 133. EUROPE NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 134. EUROPE NEUROMODULATION MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 135. EUROPE NEUROMODULATION MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 136. EUROPE NEUROMODULATION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 137. MIDDLE EAST NEUROMODULATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 138. MIDDLE EAST NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 139. MIDDLE EAST NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2017-2032 (USD MILLION)
TABLE 140. MIDDLE EAST NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 141. MIDDLE EAST NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2017-2032 (USD MILLION)
TABLE 142. MIDDLE EAST NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 143. MIDDLE EAST NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 144. MIDDLE EAST NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 145. MIDDLE EAST NEUROMODULATION MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 146. MIDDLE EAST NEUROMODULATION MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 147. MIDDLE EAST NEUROMODULATION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 148. AFRICA NEUROMODULATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 149. AFRICA NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 150. AFRICA NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2017-2032 (USD MILLION)
TABLE 151. AFRICA NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 152. AFRICA NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2017-2032 (USD MILLION)
TABLE 153. AFRICA NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 154. AFRICA NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 155. AFRICA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 156. AFRICA NEUROMODULATION MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 157. AFRICA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 158. AFRICA NEUROMODULATION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 159. GLOBAL NEUROMODULATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 160. ASEAN NEUROMODULATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 161. ASEAN NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 162. ASEAN NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2017-2032 (USD MILLION)
TABLE 163. ASEAN NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 164. ASEAN NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2017-2032 (USD MILLION)
TABLE 165. ASEAN NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 166. ASEAN NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 167. ASEAN NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 168. ASEAN NEUROMODULATION MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 169. ASEAN NEUROMODULATION MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 170. ASEAN NEUROMODULATION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 171. GCC NEUROMODULATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 172. GCC NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 173. GCC NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2017-2032 (USD MILLION)
TABLE 174. GCC NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 175. GCC NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2017-2032 (USD MILLION)
TABLE 176. GCC NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 177. GCC NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 178. GCC NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 179. GCC NEUROMODULATION MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 180. GCC NEUROMODULATION MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 181. GCC NEUROMODULATION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 182. EUROPEAN UNION NEUROMODULATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 183. EUROPEAN UNION NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 184. EUROPEAN UNION NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2017-2032 (USD MILLION)
TABLE 185. EUROPEAN UNION NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 186. EUROPEAN UNION NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2017-2032 (USD MILLION)
TABLE 187. EUROPEAN UNION NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 188. EUROPEAN UNION NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 189. EUROPEAN UNION NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 190. EUROPEAN UNION NEUROMODULATION MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 191. EUROPEAN UNION NEUROMODULATION MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 192. EUROPEAN UNION NEUROMODULATION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 193. BRICS NEUROMODULATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 194. BRICS NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 195. BRICS NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2017-2032 (USD MILLION)
TABLE 196. BRICS NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 197. BRICS NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2017-2032 (USD MILLION)
TABLE 198. BRICS NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 199. BRICS NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 200. BRICS NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 201. BRICS NEUROMODULATION MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 202. BRICS NEUROMODULATION MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 203. BRICS NEUROMODULATION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 204. G7 NEUROMODULATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 205. G7 NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 206. G7 NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2017-2032 (USD MILLION)
TABLE 207. G7 NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 208. G7 NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2017-2032 (USD MILLION)
TABLE 209. G7 NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 210. G7 NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 211. G7 NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 212. G7 NEUROMODULATION MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 213. G7 NEUROMODULATION MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 214. G7 NEUROMODULATION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 215. NATO NEUROMODULATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 216. NATO NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 217. NATO NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2017-2032 (USD MILLION)
TABLE 218. NATO NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 219. NATO NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2017-2032 (USD MILLION)
TABLE 220. NATO NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 221. NATO NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 222. NATO NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 223. NATO NEUROMODULATION MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 224. NATO NEUROMODULATION MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 225. NATO NEUROMODULATION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 226. GLOBAL NEUROMODULATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 227. UNITED STATES NEUROMODULATION MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 228. UNITED STATES NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 229. UNITED STATES NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2017-2032 (USD MILLION)
TABLE 230. UNITED STATES NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 231. UNITED STATES NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2017-2032 (USD MILLION)
TABLE 232. UNITED STATES NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 233. UNITED STATES NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 234. UNITED STATES NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 235. UNITED STATES NEUROMODULATION MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 236. UNITED STATES NEUROMODULATION MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 237. UNITED STATES NEUROMODULATION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 238. CANADA NEUROMODULATION MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 239. CANADA NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 240. CANADA NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2017-2032 (USD MILLION)
TABLE 241. CANADA NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 242. CANADA NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2017-2032 (USD MILLION)
TABLE 243. CANADA NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 244. CANADA NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 245. CANADA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 246. CANADA NEUROMODULATION MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 247. CANADA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 248. CANADA NEUROMODULATION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 249. MEXICO NEUROMODULATION MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 250. MEXICO NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 251. MEXICO NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2017-2032 (USD MILLION)
TABLE 252. MEXICO NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 253. MEXICO NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2017-2032 (USD MILLION)
TABLE 254. MEXICO NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 255. MEXICO NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 256. MEXICO NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 257. MEXICO NEUROMODULATION MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 258. MEXICO NEUROMODULATION MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 259. MEXICO NEUROMODULATION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 260. BRAZIL NEUROMODULATION MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 261. BRAZIL NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 262. BRAZIL NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2017-2032 (USD MILLION)
TABLE 263. BRAZIL NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 264. BRAZIL NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2017-2032 (USD MILLION)
TABLE 265. BRAZIL NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 266. BRAZIL NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 267. BRAZIL NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 268. BRAZIL NEUROMODULATION MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 269. BRAZIL NEUROMODULATION MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 270. BRAZIL NEUROMODULATION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 271. UNITED KINGDOM NEUROMODULATION MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 272. UNITED KINGDOM NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 273. UNITED KINGDOM NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2017-2032 (USD MILLION)
TABLE 274. UNITED KINGDOM NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 275. UNITED KINGDOM NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2017-2032 (USD MILLION)
TABLE 276. UNITED KINGDOM NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 277. UNITED KINGDOM NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 278. UNITED KINGDOM NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 279. UNITED KINGDOM NEUROMODULATION MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 280. UNITED KINGDOM NEUROMODULATION MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 281. UNITED KINGDOM NEUROMODULATION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 282. GERMANY NEUROMODULATION MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 283. GERMANY NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 284. GERMANY NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2017-2032 (USD MILLION)
TABLE 285. GERMANY NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 286. GERMANY NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2017-2032 (USD MILLION)
TABLE 287. GERMANY NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 288. GERMANY NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 289. GERMANY NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 290. GERMANY NEUROMODULATION MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 291. GERMANY NEUROMODULATION MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 292. GERMANY NEUROMODULATION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 293. FRANCE NEUROMODULATION MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 294. FRANCE NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 295. FRANCE NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2017-2032 (USD MILLION)
TABLE 296. FRANCE NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 297. FRANCE NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2017-2032 (USD MILLION)
TABLE 298. FRANCE NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 299. FRANCE NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 300. FRANCE NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 301. FRANCE NEUROMODULATION MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 302. FRANCE NEUROMODULATION MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 303. FRANCE NEUROMODULATION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 304. RUSSIA NEUROMODULATION MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 305. RUSSIA NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 306. RUSSIA NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2017-2032 (USD MILLION)
TABLE 307. RUSSIA NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 308. RUSSIA NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2017-2032 (USD MILLION)
TABLE 309. RUSSIA NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 310. RUSSIA NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 311. RUSSIA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 312. RUSSIA NEUROMODULATION MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 313. RUSSIA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 314. RUSSIA NEUROMODULATION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 315. ITALY NEUROMODULATION MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 316. ITALY NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 317. ITALY NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2017-2032 (USD MILLION)
TABLE 318. ITALY NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 319. ITALY NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2017-2032 (USD MILLION)
TABLE 320. ITALY NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 321. ITALY NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 322. ITALY NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 323. ITALY NEUROMODULATION MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 324. ITALY NEUROMODULATION MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 325. ITALY NEUROMODULATION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 326. SPAIN NEUROMODULATION MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 327. SPAIN NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 328. SPAIN NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2017-2032 (USD MILLION)
TABLE 329. SPAIN NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 330. SPAIN NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2017-2032 (USD MILLION)
TABLE 331. SPAIN NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 332. SPAIN NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 333. SPAIN NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 334. SPAIN NEUROMODULATION MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 335. SPAIN NEUROMODULATION MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 336. SPAIN NEUROMODULATION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 337. CHINA NEUROMODULATION MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 338. CHINA NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 339. CHINA NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2017-2032 (USD MILLION)
TABLE 340. CHINA NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 341. CHINA NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2017-2032 (USD MILLION)
TABLE 342. CHINA NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 343. CHINA NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 344. CHINA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 345. CHINA NEUROMODULATION MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 346. CHINA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 347. CHINA NEUROMODULATION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 348. INDIA NEUROMODULATION MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 349. INDIA NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 350. INDIA NEUROMODULATION MARKET SIZE, BY DEEP BRAIN STIMULATION, 2017-2032 (USD MILLION)
TABLE 351. INDIA NEUROMODULATION MARKET SIZE, BY SACRAL NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 352. INDIA NEUROMODULATION MARKET SIZE, BY SPINAL CORD STIMULATION, 2017-2032 (USD MILLION)
TABLE 353. INDIA NEUROMODULATION MARKET SIZE, BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 354. INDIA NEUROMODULATION MARKET SIZE, BY VAGUS NERVE STIMULATION, 2017-2032 (USD MILLION)
TABLE 355. INDIA NEUROMODULATION MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 356. INDIA NEUROMODULATION MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 357. INDIA NEUROMODULATION MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 358. INDIA NEUROMODULATION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 359. JAPAN NEUROMODULATION MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 360. JAPAN NEUROMODULATION MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (US

Companies Mentioned

  • Abbott Laboratories
  • BioControl by Merck
  • BioElectronics Corporation
  • Boston Scientific Corporation
  • EndoStim, Inc.
  • Impulse Dynamics
  • Livanova
  • Mainstay Medical
  • Medtronic PLC
  • MicroTransponde
  • NeuroMetrix
  • Neuronetics, Inc.
  • NeuroPace, Inc.
  • NeuroSigma, Inc.
  • Nevro Corp.
  • Saluda Medical
  • SceneRay Corporation, Limited
  • Soterix Medical
  • Synapse Biomedical

Table Information

Report AttributeDetails
No. of Pages185
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 7.06 Billion
Forecasted Market Value ( USD ) by 2032 $ 10.65 Billion
Compound Annual Growth Rate7.0%
Regions CoveredGlobal
No. of Companies Mentioned19

Related Topics

Related Reports

Neuromodulation Devices Market - Global Forecast 2026-2032 - Product Image

Neuromodulation Devices Market - Global Forecast 2026-2032

  • Report
  • 189 Pages
  • Global
From
Neuromodulation Market by Technology, Stimulation Type, Application, End User, and Region - Global Forecast to 2030 - Product Image

Neuromodulation Market by Technology, Stimulation Type, Application, End User, and Region - Global Forecast to 2030

  • Report
  • 367 Pages
  • Global
From
Neuromodulation Devices - Market Insights, Competitive Landscape, and Market Forecast - 2032 - Product Image

Neuromodulation Devices - Market Insights, Competitive Landscape, and Market Forecast - 2032

  • Report
  • 150 Pages
  • Global
From
Neuromodulation Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031 - Product Image

Neuromodulation Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

  • Report
  • 180 Pages
  • Global
From
Neuromodulation Market Report by Technology, Biomaterial, Application, and Region 2026-2034 - Product Image

Neuromodulation Market Report by Technology, Biomaterial, Application, and Region 2026-2034

  • Report
  • 146 Pages
  • Global
From

About the Neuromodulation Device Market

Neuromodulation devices are medical devices used to treat neurological disorders and chronic pain. These devices are used in a variety of surgical procedures, such as deep brain stimulation, spinal cord stimulation, and sacral nerve stimulation. Neuromodulation devices are designed to deliver electrical stimulation to the nervous system, which can help reduce pain, improve movement, and restore normal functioning. Neuromodulation devices are used in a variety of surgical procedures, including neurosurgery, orthopedic surgery, and plastic surgery. In neurosurgery, neuromodulation devices are used to treat conditions such as Parkinson's disease, epilepsy, and chronic pain. In orthopedic surgery, neuromodulation devices are used to treat conditions such as spinal cord injuries, chronic pain, and muscle spasms. In plastic surgery, neuromodulation devices are used to treat conditions such as facial paralysis and facial nerve damage. Some of the companies in the neuromodulation device market include Medtronic, Boston Scientific, St. Jude Medical, Abbott, and Cyberonics. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.